1-1 of 1
Michael Hawkins
Close
Sort by
Journal Articles

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Clinical Trials & Observations
Jeff Sharman, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak
Journal: Blood
Blood (2015) 125 (15): 2336–2343.
https://doi.org/10.1182/blood-2014-08-595934
Published: 2015
Includes: Supplemental data